FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3131502707> ?p ?o ?g. }

• W3131502707 endingPage "454" @default.
• W3131502707 startingPage "438" @default.
• W3131502707 abstract "Calcitonin gene-related peptide (CGRP) inhibitors were introduced in the United States (US) in 2018. To understand the changing patterns of preventive treatment following the introduction of these new agents, we must first characterize the patterns which preceded their introduction.To characterize the burden, unmet need, and treatment patterns in patients with migraine initiating preventive migraine medications before the introduction of CGRP inhibitors in the US.Between March 2016 and October 2017, we enrolled episodic (EM) and chronic migraine (CM) patients initiating or changing preventive treatment at primary care or neurology clinic visits in the US, in a real-world observational study using a prospective cohort design. At baseline and monthly thereafter for 6 months, we collected data from study sites and patients on migraine frequency, treatment modifications, migraine impact on functioning, and work productivity for a descriptive analysis of migraine patient experience and treatment patterns.From the sample of 234 completers, 118 had EM (50.4%) and 116 had CM (49.6%). Mean age at enrollment was 41 years (SD = 12) and mean age at first migraine diagnosis was 22 years (SD = 11). Most participants were females (n = 204/234; 87.2%) and white (n = 178/234; 76.1%). The majority (n = 164/234; 70.1%) had not used preventive migraine treatment in the 5 years prior to enrollment (treatment naïve). At baseline, mean monthly migraine days were 9.6 days (SD = 5.0) for the preventive treatment naïve group and 12.4 days (SD = 7.0) for treatment experienced patients. The majority had severe Migraine Disability Assessment (Grade IV, total score ≥21), including 67.1% (n = 110/164) of the preventive treatment naïve and 77.1% (n = 54/70) of the preventive treatment experienced patients. Headache Impact Test total scores indicating severe impairment (score >59) occurred in 88.4% (n = 145/164) of the treatment naïve and 88.6% (n = 62/70) of treatment experienced patients. Mean work productivity loss as measured by the Work Productivity and Activity Impairment questionnaire in the subsample of employed patients was 53.3% loss. The most used acute medications at baseline were nonsteroidal anti-inflammatory agents (n = 124/234; 53.0%), acetaminophen-based products (n = 112/234; 47.9%), and triptans (n = 105/234; 44.9%). The most commonly initiated preventive treatments were topiramate (n = 100/234; 42.7%), tricyclic antidepressants (n = 39/234; 16.7%), beta-blockers (n = 26/234; 11.1%), and onabotulinumtoxinA (n = 24/234; 10.3%). Over the 6-month follow-up period, almost half of patients (n = 116/234, 49.6%) modified their preventive treatment and discontinued treatment (n = 88/312 total modifications; 28.2%) or modified their pattern of use by increasing, decreasing, or skipping doses (n = 224/312 total modifications; 71.8%), often without seeking medical advice. Avoiding side effects was the main reason reported among patients who discontinued (n = 52/88; 59.1%), decreased frequency or dose (n = 37/89; 41.6%), and skipped doses (n = 29/86; 33.7%). Perceived lack of efficacy was another frequent reason reported among those who discontinued (n = 20/88; 22.7%), decreased frequency or dose (n = 15/89; 16.9%), and skipped doses (n = 18/86; 20.9%). Despite initiation of preventive treatment and improvements observed in number of headache and migraine days, migraine patients continued to experience substantial disability, headache impact, and reduced productivity throughout the 6-month follow-up period.Prior to 2018, the burden of migraine was high for patients initiating preventive treatments. Despite having more than 9 days of migraine per month on average, the majority (70.1%) of patients initiating prevention had been treatment naïve, indicating underuse of preventive treatments. The preventive treatments used in this study were poorly tolerated and were reported by patients to lack efficacy, resulting in suboptimal adherence. The high discontinuation rates suggest that the preventive medications being offered during the period of the study did not meet the treatment needs of patients. In addition, the decisions by about half of patients to alter their prescribed treatment plan without consulting their provider can pose substantial health risks. These findings pertain to the broad set of preventive treatments initiated in this study and do not support inferences about individual preventive treatments, due to limitations in sample size. These findings suggest the need for more effective and better tolerated preventive treatment options." @default.
• W3131502707 created "2021-03-01" @default.
• W3131502707 creator A5000448269 @default.
• W3131502707 creator A5002363670 @default.
• W3131502707 creator A5035244816 @default.
• W3131502707 creator A5044465619 @default.
• W3131502707 creator A5048405172 @default.
• W3131502707 creator A5057290642 @default.
• W3131502707 creator A5064341657 @default.
• W3131502707 creator A5069608132 @default.
• W3131502707 creator A5070961430 @default.
• W3131502707 creator A5072623389 @default.
• W3131502707 date "2021-02-16" @default.
• W3131502707 modified "2023-09-29" @default.
• W3131502707 title "Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study" @default.
• W3131502707 cites W1973124376 @default.
• W3131502707 cites W2005239637 @default.
• W3131502707 cites W2009222901 @default.
• W3131502707 cites W2035901223 @default.
• W3131502707 cites W2047041272 @default.
• W3131502707 cites W2047455969 @default.
• W3131502707 cites W204766049 @default.
• W3131502707 cites W2065369272 @default.
• W3131502707 cites W2073160193 @default.
• W3131502707 cites W2086325363 @default.
• W3131502707 cites W2094473459 @default.
• W3131502707 cites W2097720630 @default.
• W3131502707 cites W2104531364 @default.
• W3131502707 cites W2108490520 @default.
• W3131502707 cites W2128653531 @default.
• W3131502707 cites W2156341109 @default.
• W3131502707 cites W2345369601 @default.
• W3131502707 cites W2528453852 @default.
• W3131502707 cites W2549116677 @default.
• W3131502707 cites W2586783269 @default.
• W3131502707 cites W2763655322 @default.
• W3131502707 cites W2791018156 @default.
• W3131502707 cites W2791199217 @default.
• W3131502707 cites W2910809224 @default.
• W3131502707 cites W2936553526 @default.
• W3131502707 cites W2939790627 @default.
• W3131502707 cites W2954031825 @default.
• W3131502707 cites W2965415078 @default.
• W3131502707 doi "https://doi.org/10.1111/head.14053" @default.
• W3131502707 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8048891" @default.
• W3131502707 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33594686" @default.
• W3131502707 hasPublicationYear "2021" @default.
• W3131502707 type Work @default.
• W3131502707 sameAs 3131502707 @default.
• W3131502707 citedByCount "15" @default.
• W3131502707 countsByYear W31315027072021 @default.
• W3131502707 countsByYear W31315027072022 @default.
• W3131502707 countsByYear W31315027072023 @default.
• W3131502707 crossrefType "journal-article" @default.
• W3131502707 hasAuthorship W3131502707A5000448269 @default.
• W3131502707 hasAuthorship W3131502707A5002363670 @default.
• W3131502707 hasAuthorship W3131502707A5035244816 @default.
• W3131502707 hasAuthorship W3131502707A5044465619 @default.
• W3131502707 hasAuthorship W3131502707A5048405172 @default.
• W3131502707 hasAuthorship W3131502707A5057290642 @default.
• W3131502707 hasAuthorship W3131502707A5064341657 @default.
• W3131502707 hasAuthorship W3131502707A5069608132 @default.
• W3131502707 hasAuthorship W3131502707A5070961430 @default.
• W3131502707 hasAuthorship W3131502707A5072623389 @default.
• W3131502707 hasBestOaLocation W31315027071 @default.
• W3131502707 hasConcept C118303440 @default.
• W3131502707 hasConcept C118552586 @default.
• W3131502707 hasConcept C126322002 @default.
• W3131502707 hasConcept C163170386 @default.
• W3131502707 hasConcept C16568411 @default.
• W3131502707 hasConcept C170493617 @default.
• W3131502707 hasConcept C187212893 @default.
• W3131502707 hasConcept C197934379 @default.
• W3131502707 hasConcept C23131810 @default.
• W3131502707 hasConcept C2777119127 @default.
• W3131502707 hasConcept C2778375690 @default.
• W3131502707 hasConcept C2778541695 @default.
• W3131502707 hasConcept C2780564907 @default.
• W3131502707 hasConcept C2910587157 @default.
• W3131502707 hasConcept C71924100 @default.
• W3131502707 hasConcept C72563966 @default.
• W3131502707 hasConceptScore W3131502707C118303440 @default.
• W3131502707 hasConceptScore W3131502707C118552586 @default.
• W3131502707 hasConceptScore W3131502707C126322002 @default.
• W3131502707 hasConceptScore W3131502707C163170386 @default.
• W3131502707 hasConceptScore W3131502707C16568411 @default.
• W3131502707 hasConceptScore W3131502707C170493617 @default.
• W3131502707 hasConceptScore W3131502707C187212893 @default.
• W3131502707 hasConceptScore W3131502707C197934379 @default.
• W3131502707 hasConceptScore W3131502707C23131810 @default.
• W3131502707 hasConceptScore W3131502707C2777119127 @default.
• W3131502707 hasConceptScore W3131502707C2778375690 @default.
• W3131502707 hasConceptScore W3131502707C2778541695 @default.
• W3131502707 hasConceptScore W3131502707C2780564907 @default.
• W3131502707 hasConceptScore W3131502707C2910587157 @default.
• W3131502707 hasConceptScore W3131502707C71924100 @default.
• W3131502707 hasConceptScore W3131502707C72563966 @default.
• W3131502707 hasFunder F4320307105 @default.

• next